Israeli organ hologram company RealView imaging has raised $10 million in a round of funding led by the Chinese investment firm LongTec. The infusion of new capital will be used by the startup to expand its technological innovations.
RealView Imaging’s system projects a 3D holographic video stream or 3D still images “floating in the air”, based on real-time or previously acquired 3D data received from existing medical imaging modalities and navigation technologies. The projected volumetric 3D content is dynamic, in color and of high resolution, providing the viewer with a unique “ultra-realistic” viewing experience, unlike anything that exists today. The projected holograms can be viewed from different angles while seen in a precise spatial location and contain all the visual depth cues, as if the projected objects were truly there. Naturally, as the images are digital, they can be rotated or otherwise manipulated as required by literally touching them in real-time.
The company boasts that its system introduces multiple proprietary 3D user interface capabilities, allowing real-time marking, calibration and simulation “with and within” the floating volumes. This direct and intuitive user interface provides a whole new set of capabilities thereby revolutionizing the way medical professionals are able to interact with 3D information.
RealView Imaging’s systems, it asserts, are complementary to all the currently available 3D modalities and navigation tools which generate 3D volumetric content and present it over existing 2D screens. The holographic video stream or 3D still images presented by RealView’s system are based on these existing 3D acquisition modalities and navigation technologies (3D-CT, 3D Rotational Angiography, 3D-Ultrasound and others). With the growing number of installations of these systems and the increasing clinical evidence on the value of 3D for specific clinical procedures, RealView’s products are targeted to empower the users of these systems and provide them the freedom for unbounded interaction with this underutilized medical information.
RealView was founded in 2008 by CEO Aviad Kaufman, president and VP R&D Shaul Gelman, and scientific director Dr. Carmel Rotschild, with a seed investment from chairman Dr. Shimon Eckhouse. The company conducted its clinical trial together with Philips Healthcare and Schneider’s Children Medical Center.
In a statement Eckhouse commented, “We’re now planning to bring our products to market for the first time. We’re delighted with the cooperation with LongTec, in view of their extensive know-how in the international medical markets and their strategic positioning in the Chinese market.”